Strike two against an antibody approach to treating type 1 diabetes. Otelixizumab, the protein GlaxoSmithKline and Tolerx were testing in phase III, failed to improve symptoms in recently diagnosed patients with the autoimmune form of the disease.The failure was not judged as a surprise by some industry observers as a related molecule, teplizumab, failed for Eli Lilly and MacroGenics in October 2010. However, it is certainly a disappointment in terms of advancing new treatments for this disease - the product is one of just three late-stage candidates for type 1 that does not rely on insulin replacement.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions